Omnicell (NASDAQ:OMCL) Updates Q4 Earnings Guidance

by · The Cerbat Gem

Omnicell (NASDAQ:OMCL – Get Free Report) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share guidance of $0.55-$0.62 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $295-$305 million, compared to the consensus revenue estimate of $287.85 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Price Performance

Omnicell stock traded up $0.03 during mid-day trading on Friday, hitting $48.67. The company’s stock had a trading volume of 683,792 shares, compared to its average volume of 528,146. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $2.24 billion, a P/E ratio of -124.79, a P/E/G ratio of 58.48 and a beta of 0.83. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74. The stock’s fifty day moving average price is $43.34 and its two-hundred day moving average price is $35.32.

Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the previous year, the business posted $0.29 earnings per share. The firm’s quarterly revenue was down 7.4% compared to the same quarter last year. Research analysts forecast that Omnicell will post 0.64 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Barclays boosted their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, Wells Fargo & Company lifted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and an average target price of $49.14.

Read Our Latest Report on Omnicell

Omnicell Company Profile

(Get Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Articles